EP300 and prostate carcinoma: Significantly, the CBP/p300 KAT inhibitor A-485 [29] and BD inhibitor CCS1477 [50] have antitumor activity in vivo in mouse models of prostate cancer and the latter also shows promising clinical activity in human patients with prostate cancer [50].